Abstract:
Modern transfusion practice is associated with an increased risk of transmitting viral agents because of the changing nature of the patients and of the therapeutic blood products. More immunosuppressed patients are receiving blood released faster and with more elaborate blood components. In addition to the classically recognized importance of hepatitis B virus (itself disseminated most efficiently by contamination of products derived from large pools of plasma containing many donations) other agents are assuming increasing importance. They frequently display one or more of the predisposing characteristics of prolonged viraemia, inapparent infections and a carrier or latent state. Some of these infections like cytomegalovirus and the human T-cell leukaemia virus are transmitted only by the cellular component of blood. Others like B and non-A, non-B hepatitis and the putative agent(s) of the newly recognized acquired immune deficiency syndrome can also be transmitted in the plasma or its products. Not all the agents transmitted cause severe illness, however; human parvovirus appears to cause no clinical illness when transmitted by transfusion and infections with non-A, non-B hepatitis are largely detected only by elevations in transaminase levels. Screening tests for the presence of these agents in donor blood or for evidence of infection by them in donors continue to be studied. Other approaches, related in particular to the selection of donors, are becoming increasingly important where serological screening tests are not available.
Keywords: Acquired Immunodeficiency Syndrome/TRANSMISSION Adult Blood Transfusion/*ADVERSE EFFECTS Cell Separation Child Cytomegalovirus Infections/TRANSMISSION Female Hepatitis B/TRANSMISSION Hepatitis C/TRANSMISSION Human HTLV-BLV Viruses Infant, Newborn Leukocytes/TRANSPLANTATION Parvoviridae Infections/TRANSMISSION Plasma/MICROBIOLOGY Retroviridae Infections/TRANSMISSION Virus Diseases/PREVENTION & CONTROL/*TRANSMISSION JOURNAL ARTICLE REVIEW
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1985. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1985. The state of the art may have changed since the publication date.
